Contrasting Signaling Pathways of {alpha}1A- and {alpha}1B-Adrenergic Receptor Subtype Activation of Phosphatidylinositol 3-Kinase and Ras in Transfected NIH3T3 Cells

Zhuo-Wei Hu, Xiao-You Shi, Richard Z. Lin1 and Brian B. Hoffman

Geriatric Research, Education and Clinical Center Veterans Affairs Palo Alto Health Care System Palo Alto, California 94304
Department of Medicine Stanford University School of Medicine Stanford, California 94305


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
Activation of protein kinases is an important intermediate step in signaling pathways of many G protein-coupled receptors including {alpha}1-adrenergic receptors. The present study was designed to investigate the capacity of the three cloned subtypes of human {alpha}1-receptors, namely, {alpha}1A, {alpha}1B and {alpha}1D, to activate phosphatidylinositol 3-kinase (PI 3-kinase) and p21ras in transfected NIH3T3 cells. Norepinephrine activated PI 3-kinase in cells expressing human {alpha}1A and {alpha}1B via pertussis toxin-insensitive G proteins; {alpha}1D-receptors did not detectably activate this kinase. Transient transfection of NIH 3T3 cells with the {alpha}-subunit of the G protein transducin ({alpha}t) a scavenger of ß{gamma}-subunits released from activated G proteins, inhibited {alpha}1B-receptor but not {alpha}1A-receptor-stimulated PI 3-kinase activity. Stimulation of both {alpha}1A- and {alpha}1B-receptors activated p21ras and stimulated guanine nucleotide exchange on Ras protein. Overexpression of a dominant negative mutant of p21ras attenuated {alpha}1B-receptor but not {alpha}1A-receptor activation of PI 3-kinase. Overexpression of a dominant negative mutant of PI 3-kinase attenuated {alpha}1A- but not {alpha}1B-receptor-stimulated mitogen-activated protein kinase activity. These results demonstrate the capacity for heterologous signaling of the {alpha}1-adrenergic receptor subtypes in promoting cellular responses in NIH3T3 cells.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
{alpha}1-Adrenergic receptors, members of the class of G protein-coupled receptors, mediate many of the important physiological effects of catecholamines such as norepinephrine or epinephrine (1, 2). {alpha}1-Adrenergic receptors may play a role in many human diseases, such as atherosclerosis and hypertension (3, 4), restenosis after coronary dilation (5), myocardial hypertrophy, and cardiac arrhythmia (6, 7). There are at least three subtypes of {alpha}1-receptors expressed in human vascular smooth muscle cells (VSMCs) and many other cells, namely, {alpha}1A-, {alpha}1B-, and {alpha}1D-receptors (8, 9). It is generally accepted that activation of all three subtypes of {alpha}1-receptors increases hydrolysis of phosphatidylinositol (PI) 4,5-bisphosphate to inositol (1, 4, 5)-triphosphate and diacylglycerol via the {alpha}-subunit of Gq, a family of pertussis toxin (PTx)-insensitive G proteins (10, 11). Production of inositol triphosphate and diacylglycerol can also occur via activation of phospholipase Cß mediated by ß{gamma}-subunits released from G proteins such as Go and Gi (12). It is becoming increasingly clear that {alpha}1-receptors activate other signaling pathways; for example, {alpha}1-receptors activate phospholipase D in brain and promote the release of arachidonic acid via activation of phospholipase A2 via PTx-sensitive G proteins (13, 14). Recent studies indicate that {alpha}1-adrenergic receptors may share tyrosine protein kinase/Ras/mitogen-activated protein (MAP) kinases signaling pathways with peptide growth factors to stimulate growth responses in several types of cells including myocytes and VSMCs (Ref. 15 and Z.-W. Hu, X. Y. Shi, R. Z. Lin, and B. B. Hoffman, submitted for publication).

Phosphatidylinositol 3-kinase (PI 3-kinase) is a kinase that plays an important role in mediation of mitogenic actions of many peptide growth factors and G protein-coupled receptors in various types of cells (for reviews see Refs. 17, 18). PI-3 kinase has been implicated in the regulation of cell growth by receptor tyrosine kinases (19, 20), cytokine receptors (21), and G protein-coupled receptors (22, 23). PI 3-kinase mediates a number of intracellular events including the PKC-independent serine phosphorylation and activation of a ribosomal S6 kinase family designated p70/p90S6K (24). PI 3-kinases and ribosomal S6 kinases play a major part in mitogen-stimulated increase in protein synthesis and changes in cytosolic structure of growing and dividing cells. Mitogens such as platelet-derived growth factor (PDGF), insulin, and insulin-like growth factor (IGF) activate PI 3-kinase leading to rapid phosphorylation of phosphatidylinositol (4, 5)-diphosphate at the D-3 position of the inositol ring to form phosphatidylinositol (3, 4, 5)-triphosphate (25). Increasing evidence suggests that this product is involved in the regulation of the actin cytoskeleton that plays a critical role in a number of cellular processes including motility, chemotaxis, and cell division (26, 27).

There are multiple forms of PI 3-kinase with distinct mechanisms of regulation and different substrate specificities in mammalian cells; these enzymes are activated both by peptide growth factors and G protein-coupled receptor agonists. The first identified PI 3-kinase is a heterodimer consisting of a p85-regulatory subunit with SRC homology 2 (SH2) domains and a p110 catalytic subunit (28). Another PI 3-kinase has been described; this isoform consisted of a p110 monomeric subunit that is activated independently of a p85-regulatory subunit (29). A major mode of activation of the heterodimeric PI 3-kinase by growth factors likely involves docking of the kinase through SH2 domains on the p85 subunit to phosphorylated tyrosine residues(s) on receptor tyrosine kinases (30). This PI-3 kinase isoform is also directly activated by ß{gamma}-subunits released from activated G proteins in platelets (31) and by Gi in cell lines expressing {alpha}2A-adrenergic receptors (22). Activation of the heterodimeric PI 3-kinase has a complex relationship with p21ras activation. Activation of PI 3-kinase may occur via Ras-dependent (32) or independent (33) pathways; PI 3-kinase may function as a target of P21ras (34) in some cells or function upstream of p21ras in others (22, 35). We recently demonstrated in human VSMCs, likely expressing the three subtypes of {alpha}1-receptors, that {alpha}1 receptor-stimulated mitogenesis is associated with activation of PI 3-kinase (36). In those cells, {alpha}1-receptor activation of PI 3-kinase is mediated by a PTx-sensitive G protein(s), and PI 3-kinase activity is associated with activation of p21Ras and increased tyrosine protein kinase activity. However, there is little specific information about signaling pathways that mediate {alpha}1-receptor subtype stimulation of PI 3-kinase, particularly in a model system where potential differences in the signaling pathways used by the three cloned {alpha}1-receptor subtypes could be discerned.

Increasing evidence suggests that each of the subtypes of {alpha}1-receptors may activate overlapping or potentially distinct signaling pathways (2, 13). However, little is known about the potential biological significance of the various specific {alpha}1-receptor subtypes being expressed in same cells. Availability of expression vectors containing cDNAs encoding each of the {alpha}1-receptor subtypes provides an approach to the question of which subtype(s) of {alpha}1-receptors mediate activation of PI-3 kinase. NIH3T3 cells stably transfected with each of three subtypes of {alpha}1-receptors provides an interesting model system as these cells have been extensively characterized in terms of classical growth factor-stimulated mitogenesis. In the present study, we have found that stimulation both {alpha}1A- and {alpha}1B-, but not {alpha}1D-receptor subtypes of human {alpha}1-receptors, stably expressed in these cells, activated PI 3-kinase. The results demonstrate that {alpha}1A- and {alpha}1B-receptor subtypes activated PI 3-kinase via different subunits of G proteins; and there were differentiable patterns of activation of p21Ras protein and MAP kinase cascades by {alpha}1-receptor subtypes in these cells.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
NIH3T3 cells were used for transfection of control vectors or expression vectors containing three subtypes ({alpha}1A, {alpha}1B, and {alpha}1D) of human {alpha}1-receptors. To confirm functional expression of each of the three subtypes of {alpha}1-receptors in NIH3T3 cells, {alpha}1 receptor-stimulated expression of c-fos mRNA was measured in NIH3T3 cells stably expressing {alpha}1A, {alpha}1B, and {alpha}1D receptors. Induction of c-fos mRNA was selected as a functional index of biologically significant expression of {alpha}1-receptors (37). Stimulation of the cells with norepinephrine caused similar increases in expression of the c-fos gene in the cells transfected with each of the three subtypes of {alpha}1-receptors, suggesting that these cells expressed functional receptors for each of the three subtypes (Fig. 1AGo). Norepinephrine did not stimulate c-fos expression in the wild-type cells (data not shown). Also, norepinephrine-stimulated increased expression of c-fos mRNA was attenuated by the {alpha}1-receptor antagonist prazosin (Fig. 1BGo).



View larger version (35K):
[in this window]
[in a new window]
 
Figure 1. Characterization of Functional Expression of {alpha}1-Receptor Subtypes

A, NIH3T3 cells, which individually stably expressed each of the three subtypes of {alpha}1-receptors, were grown to confluence in a series of 100-cm2 dishes in DMEM containing 10% FBS in the presence of geneticin (100 ng/ml) for 24 h. The near-confluent 3T3 cells were then incubated with serum-free DMEM for 24 h. After norepinephrine or vehicle treatment for 60 min, cells were harvested for isolation of total RNA, and Northern blots were performed as described in Materials and Methods. The data are representative of three experiments. Panel B demonstrates that the {alpha}1-receptor antagonist prazosin blocked the induction of norepinephrine-stimulated c-fos mRNA expression (mean ± SEM of four experiments).

 
Norepinephrine did not activate PI-3 kinase activity in wild-type NIH3T3 cells or in cells transfected with control vectors, confirming that these cells do not express endogenous {alpha}1-receptors. As illustrated in Fig. 2Go, norepinephrine (10 µM) stimulated activation of PI 3-kinase in NIH3T3 cells transfected with {alpha}1A- or {alpha}1B-receptors. However, although cells transfected with {alpha}1D-receptors reproducibly had an increased basal activity of PI 3-kinase compared with cells transfected with control vectors, norepinephrine did not significantly increase PI 3-kinase activity in cells transfected with the {alpha}1D-receptors. Interestingly, the increased basal activity of PI 3-kinase in cells transfected {alpha}1D-receptors was inhibited by the {alpha}1-receptor antagonists, doxazosin and prazosin (data not shown). This result suggests that overexpression of {alpha}1D-receptors may spontaneously (in the absence of added agonist), albeit weakly, activate down-stream signaling mechanisms and that these antagonists are acting as inverse agonists. Norepinephrine stimulated a concentration-dependent increase in PI 3-kinase activity in cells expressing {alpha}1A- or {alpha}1B-receptors, and theses responses were blocked by {alpha}1-receptor antagonists, doxazosin and prazosin (data not shown), as we reported previously for VSMCs (36).



View larger version (39K):
[in this window]
[in a new window]
 
Figure 2. {alpha}1-Receptor Subtype-Mediated Activation of PI-3 Kinase

NIH3T3 cells, stably transfected with control vectors or expression vectors containing each of the three subtypes of human {alpha}1 receptors, were incubated for 24 h in serum-free DMEM and then pretreated with ß-receptor antagonist timolol (10 µM) and {alpha}2-receptor antagonist idazoxan (10 µM) for 2 h. Cells were then treated with vehicle or 10 µM of norepinephrine for 5 min. Cell lysates (2 mg of protein) were immunoprecipitated with anti-P85{alpha} subunit of PI-3 kinase and subjected to determination of PI-3 kinase activity as described in Materials and Methods. The autoradiogram of TLC of PI-3 kinase was exposed for 20 h. A, Data from a representative experiment. B, Data are average ± SEM of three experiments. **, P < 0.01.

 
To determine whether stimulation of PI 3-kinase in cells expressing either {alpha}1A- or {alpha}1B-receptor subtypes required PTx-sensitive G proteins, cells were incubated with PTx (50 ng/ml) for 16 h. PTx did not block norepinephrine-stimulated PI 3-kinase in cells transfected with either {alpha}1A-receptors (Fig. 3AGo, lane 4) or {alpha}1B-receptors (Fig. 3BGo, lane 4), suggesting that both of these subtypes of {alpha}1-receptors activate PI 3-kinase via PTx-insensitive G proteins in NIH3T3 cells.



View larger version (31K):
[in this window]
[in a new window]
 
Figure 3. Effects of PTx and Expression of {alpha}-Subunit of Transducin ({alpha}-Transducin) on {alpha}1-Receptor Subtype-Stimulated Activation of PI-3 Kinase

Cells expressing {alpha}1A (panel A) or {alpha}1B (panel B) receptors were grown to 70–80% of confluence and transiently transfected with {alpha}-subunit of transducin or ß1-adrenergic receptor kinase (ß-ARK) as described in Materials and Methods. Cells were incubated with serum-free DMEM for 24 h and were pretreated with PTx (100 ng/ml) or not for 16 h. Cells were then stimulated with vehicle or 10 µM norepinephrine for 5 min. Cell lysates (2 mg of protein) were prepared, immunoprecipitated with anti-p85 of PI-3 kinase antibody, and subjected to determination of PI-3 kinase as described above. The autoradiogram of TLC of PI-3 kinase was exposure for 24 h. Experiments were repeated 3 times with similar results. C, Transfection of 3T3 cells with the ß-ARK and {alpha}t genes demonstrated expression of the GRK2 protein. Cells were transiently transfected with ß-ARK, {alpha}t (10 µg), or control vector (10 µg) as described above. Cell lysates were prepared, and 100 µg of protein/sample were separated by PAGE and subjected by Western blotting as described in Materials and Methods. ß-ARK or {alpha}t was detected by an anti-GRK2 antibody or by anti-{alpha}t antibody. D, Cotransfection of 3T3 cells with the {alpha}2A-receptor gene plus either {alpha}t or GRK2. Cells were then treated with or without norepinephrine, and MAP kinase activity was measured as described in Materials and Methods. ß-ARK and {alpha}t inhibited norepinephrine-stimulated MAP kinase activity in cells epxressing {alpha}2A-receptors. Data are a representative of four experiments.

 
To investigate potential roles of {alpha}- and ß{gamma}-subunits of G proteins in activation of PI 3-kinase, cells transfected stably with {alpha}1A- or {alpha}1B-receptors were transiently transfected with the {alpha}t-construct as {alpha}t functions as a scavenger of free ß{gamma} (38). As illustrated in Fig. 3Go, overexpression of {alpha}t did not inhibit norepinephrine-stimulated activation of PI 3-kinase in cells transfected with {alpha}1A-receptors. This result suggests that either an {alpha}-subunit or a ß{gamma}-subunit not recognized by {alpha}t, released from a PTx-insensitive G protein, mediates this response (Fig. 3AGo, lane 5). However, overexpression of {alpha}t blocked norepinephrine-stimulated activation of PI 3-kinase in cells transfected with {alpha}1B-receptors (Fig. 3BGo, lane 5), suggesting that {alpha}1B-receptor-mediated activation of PI 3-kinase may be due to direct effects of ß{gamma}-subunits released from a PTx-insensitive G protein. However, overexpression of an ß-adrenergic receptor kinase peptide (ß-ARK) [also called G-protein receptor kinase-2 (GRK2)], which is a different scavenger of free ß{gamma}-subunits (22), did not inhibit either {alpha}1A- or {alpha}1B-receptor-stimulated PI 3-kinase activity. Western blotting (Fig. 3CGo) demonstrated successful expression of GRK2 as well {alpha}t in these cells. To demonstrate functional expression of GRK2 in these cells, cells were cotransfected with the {alpha}2A-adrenergic receptor gene and either {alpha}t or GRK2. GRK2 has been shown to block {alpha}2A-receptor-stimulated activation of MAP kinase (43). These cells were then treated with or without norepinephrine, and MAP kinase activity was measured. Results indicate that both {alpha}t and GRK2 attentuated the {alpha}2A-receptor-stimulated increase in activity of MAP kinase, suggesting that these two molecules functioned effectively as scavengers of the ß{gamma}-subunits released by these receptors (Fig. 3DGo).

We have previously found that {alpha}1-receptor-activated PI 3-kinase activity can be detected in anti-Ras immunocomplexes, and stimulation of {alpha}1-receptors directly increases active Ras-GTP in human VSMCs (36). Also, our previous study suggested that activation of Ras-GTP is a downstream target of PI 3-kinase after stimulation of {alpha}1-receptors in those cells. NIH3T3 cells provide an excellent model system by which to pursue the role of the individual {alpha}1-receptor subtypes in activating Ras-GTP and PI 3-kinase. We first tested which subtypes of {alpha}1-receptors activated p21Ras protein. The results indicate that norepinephrine stimulates an increase in active Ras-GTP in cells expressing either {alpha}1A- or {alpha}1B-receptors, but no measurable change was detected in cells expressing {alpha}1D-receptors (Fig. 4AGo and B). Both {alpha}1A- and {alpha}1B-receptor activation of p21Ras protein was insensitive to PTx (Fig. 4CGo). Overexpression of {alpha}-transducin did not inhibit {alpha}1A-receptor-activation of Ras-GTP. On the other hand, {alpha}t markedly inhibited {alpha}1B-receptor-stimulated activation of Ras-GTP, suggesting that ß{gamma}-subunits released from Gq were used by {alpha}1A-receptors in signaling to activate p21Ras.



View larger version (30K):
[in this window]
[in a new window]
 
Figure 4. Activation of PI 3-Kinase and p21Ras-GTP by {alpha}1-Receptors

A, Near-confluent cells stably expressing each of the three subtypes of {alpha}1-receptors were metabolically labeled with [32P]Pi in phosphate-free DMEM for 12 h. The cells were treated with vehicle or norepinephrine (10 µM) for 5 min. Cell lysates (1 mg of protein) were subjected to immunoprecipitation with an rat polyclonal antibody against H-Ras. Ras-bound GTP was determined as described in Materials and Methods. The autoradiogram after TLC was exposed for 16 h. Panel A is representative of three experiments. Panel B illustrates the mean of three experiments. Panel C illustrates norepinephrine-stimulated increases in active Ras-GTP. Cells expressing {alpha}1A- or {alpha}1B-receptors were grown for 24 h, and then the cells were transfected with {alpha}-subunit of transducin as described in Materials and Methods. Cells were metabolically labeled with [32P]Pi for 12 h. Cells were treated with vehicle or norepinephrine (10 µM) for 10 min. Cell lysates were prepared and immunoprecipitated with anti-H-Ras antibody and subjected to TLC as described above. PTx (pretreated for 16 h) had no effect on activation by {alpha}1A- or {alpha}1B-receptors, whereas expression of the {alpha}-subunit of transducin ({alpha}-transducin) inhibited the {alpha}1B but not the {alpha}1A response. Data are average ± SEM of three experiments. *, P < 0.05; **, P < 0.01.

 
To obtain additional information about the interactions between p21Ras protein and PI 3-kinase, overexpression of a dominant negative mutant of p21Ras (P21Ala15ras) was used. Transfection of cells with this dominant negative mutant of p21Ras inhibits agonist-induced increases in active Ras-GTP (39). If activation of PI 3-kinase were upstream of p21Ras activation, then transfection of cells with this mutated gene should not inhibit {alpha}1-receptor activation of PI 3-kinase. On the other hand, if activation of PI 3-kinase by stimulation of {alpha}1-receptors were a downstream target of Ras-GTP, the construct would be expected to inhibit PI 3-kinase activation. As illustrated in Fig. 5Go, overexpression of the dominant negative mutant of p21Ras blocked norepinephrine-stimulated increases in active Ras-GTP in cells expressing {alpha}1A- and {alpha}1B-receptors as expected (Fig. 5AGo). Expression of this negative mutant of p21Ras did not inhibit norepinephrine-stimulated activation of PI 3-kinases in the cells expressing {alpha}1A receptors (Fig. 5BGo). However, expression of the mutant p21ras attenuated activation of PI 3-kinase in cells expressing {alpha}1B-receptors (Fig. 5CGo), suggesting that p21Ras protein functions downstream or independently of activation of PI 3-kinase after stimulation of {alpha}1A-receptors but upstream of PI 3-kinase after stimulation of {alpha}1B-receptors.



View larger version (28K):
[in this window]
[in a new window]
 
Figure 5. Effects of Expression of Dominant Negative Mutant of p21Ras Gene on Norepinephrine-Stimulated Increase in Ras-GTP and PI 3-Kinase

A, Cells expressing {alpha}1A- or {alpha}1B-receptors were grown for 24 h, after which the cells were transfected with the p21Ala15ras dominant negative mutant (Ras15) as described in Materials and Methods. Forty eight hours after transfection, cells were metabolically labeled with [32P]Pi in Pi-free DMEM for 12 h. Cells were treated with norepinephrine (10 µM) for 10 min. Cell lysates were prepared and immunoprecipitated with anti-H-Ras antibody and subjected to TLC. The autoradiogram of the TLC plate was exposed for 16 h. Experiments were repeated twice with essentially identical results. The results indicate that both {alpha}1A- and {alpha}1B-receptor-mediated increases in Ras-GTP were blocked by expression of the negative mutation of p21Ras gene. B and C, Cells expressing {alpha}1A- or {alpha}1B-receptors were grown for 24 h, after which the cells were transfected with the p21Ala15ras dominant negative mutant as described in panel A. After 24 h incubation with serum-free DMEM, cells were treated with vehicle or norepinephrine (10 µM) for 5 min. PDGF-BB (1 nM for 5 min) was used as positive control. Cell lysates were prepared, immunoprecipitated with anti-p85 of PI 3-kinase, and kinase activity was measured. {alpha}1B- but not {alpha}1A receptor-stimulated increase in PI 3-kinases was blocked by expression of dominant negative mutation of the p21Ras gene. The autoradiogram was exposed for 16 h. Experiments were repeated twice with essentially identical results.

 
Since activation of PI 3-kinase and p21Ras protein induces activation of a series of growth or differentiation-related protein kinase cascades in various cells, we determined whether activation of specific protein kinase cascades was associated with the different subtypes of {alpha}1-receptors. As illustrated in Fig. 6Go, norepinephrine activated MAP kinase in NIH 3T3 cells expressing {alpha}1A- and {alpha}1B-receptors but not significantly in cells expressing {alpha}1D-receptors or in wild-type NIH 3T3 cells. These results were consistent with the results demonstrating that norepinephrine stimulated activation of p21Ras protein in cells expressing {alpha}1A- and {alpha}1B-receptors, but not detectably in cells expressing {alpha}1D-receptors (Fig. 4AGo). Coexpression of the P21A15ras dominant negative mutant in cells expressing {alpha}1A- and {alpha}1B-receptors significantly inhibited norepinephrine-stimulated activation of MAP kinase (Fig. 6CGo). These results demonstrate that stimulation of both {alpha}1A- and {alpha}1B-receptors activates MAP kinase at least in part via a p21Ras-dependent signaling path-way.



View larger version (43K):
[in this window]
[in a new window]
 
Figure 6. {alpha}1-Receptor Subtype Activation of MAP Kinase via p21Ras Signaling Pathways

A, The near-confluent cells stably expressing each of the three subtypes of {alpha}1-receptors were incubated with serum-free DMEM for 24 h. The cells were treated with vehicle or norepinephrine (10 µM) for 10 min. Cell lysates (400 µg of protein) were subjected to immunoprecipitation with an anti-p44ERK1 antibody. Washed immunocomplexes were subjected to in vitro assay of MAP kinase activity as described in Materials and Methods using MBP as substrate. Reaction mixtures were loaded and separated on 14% SDS-PAGE, and the dried gels were exposed to Kodak XAR-5 film at -70 C with an intensifying screen for 16 h. B, The data are mean ± SEM of three assays of MAP kinase activity. C, Cells expressing {alpha}1A- or {alpha}1B-receptors were grown for 24 h and then were transfected with the p21Ala15ras dominant negative mutant as described in Materials and Methods. Two days after transfection, cells were incubated in serum-free DMEM for 18 h. Cells were treated with vehicle or norepinephrine (10 µM) for 10 min. Cell lysates were prepared and immunoprecipitated with anti-p44ERK1 antibody and subjected to in vitro assay of MAP kinase activity as described above. The data are average ± SEM of three experiments. *, P < 0.05; **, P < 0.01.

 
We were interested in determining the potential role of PI 3-kinase in MAP kinase signaling pathways used by {alpha}1-receptor subtypes expressed in NIH3T3 cells. Figure 7Go illustrates the effects of negative dominant mutant of PI 3-kinase P85 subunit on MAP kinase activity in cells expressing {alpha}1A- and {alpha}1B-receptors. Coexpression of this mutant of PI 3-kinase p85 significantly attenuated norepinephrine-stimulated increases in kinase activities in cells expressing {alpha}1A-, but not in cells expressing {alpha}1B-receptors (Fig. 7Go), suggesting that PI 3-kinase functions as upstream component in the {alpha}1A-receptor-stimulated MAP kinase cascade. On the other hand, the MAP kinase cascade may not be a target of PI 3-kinase in {alpha}1B receptor-signaling pathways.



View larger version (52K):
[in this window]
[in a new window]
 
Figure 7. {alpha}1-Receptor Subtype Activation of MAP Kinases via a PI 3-Kinase-Dependent Signaling Pathway

Cells expressing {alpha}1A- or {alpha}1B-receptors were grown for 24 h and then the cells were transfected with a dominant negative mutant of PI 3-kinase p85 ({Delta}p85) as described in Materials and Methods. Forty eight hours after transfection, cells were incubated in serum-free DMEM for 18 h. Cells were treated with vehicle or norepinephrine (10 µM) for 10 min. Cell lysates were prepared and immunoprecipitated with anti-p44ERK1 antibody. They were subjected to in vitro assay of MAP kinase activity using MBP as substrate. The data are mean ± SEM of three assays of MAP kinase activity. *, P < 0.01.

 

    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
Stimulation of transfected {alpha}1A- or {alpha}1B-adrenergic receptors in NIH-3T3 cells led to activation of PI 3-kinase. Cells expressing {alpha}1D receptors did not stimulate PI3-kinase activity above basal values in response to norepinephrine in these experiments. In parallel experiments we found that transfection of the {alpha}1D-receptors led to norepinephrine-activation of c-fos in NIH-3T3 cells demonstrating that the {alpha}1D-receptors were being functionally expressed in the cells. The major result of these studies is that {alpha}1A- and {alpha}1B-adrenergic receptors activated downstream effectors, particularly p21ras and PI 3-kinase, by different signaling mechanisms.

Increased abundance of c-fos mRNA could be readily measured after stimulation with norepinephrine in the cells expressing in {alpha}1D-receptors, but we did not detect changes in PI 3-kinase activity in those cells. While these results clearly demonstrate functional expression of the {alpha}1D-receptors, they do not exclude the possibility that these receptors might activate this kinase in different cells or under other conditions. Using [3H]prazosin, the level of expression of each of the three {alpha}1-receptor subtypes was below the sensitivity of detection with this ligand (data not shown). Consequently, we can exclude the possibility of promiscuous coupling due to overexpression of these receptors. It has been shown previously that a low level of expression of m1 muscarinic receptors (very difficult to measure directly with a radioligand) is sufficient to activate MAP kinase cascades (40).

It is generally accepted that PTx-insensitive G proteins, particularly members of the Gq family, mediate increases in hydrolysis of PI 4,5-bisphosphate to inositol triphosphate and diacylglycerol by the three subtypes of {alpha}1-receptors (11, 41). Recent evidence suggests that signal transduction mechanisms of {alpha}1-receptors are much more complex than previously realized. For example, several studies have suggested that PTx-sensitive G proteins may also be involved in {alpha}1-receptor signaling pathways in several types of cells. Llahi and Fain (42) found that {alpha}1-receptors activate phospholipase D in the brain and promote the release of arachidonic acid via activation of phospholipase A2 via PTx-sensitive G protein (13). Stimulation of {alpha}1-receptors causes phosphorylation of c-Jun kinase mediated by a PTx-sensitive G protein (14). We recently demonstrated that {alpha}1-receptor-stimulated mitogenic effects are associated with activation of PI 3-kinase in human VSMCs and that activation of PI 3-kinase is mediated by a PTx-sensitive G protein in those cells (36). In the present study, the finding that activation of PI 3-kinase by the {alpha}1A- and {alpha}1B-receptor subtypes is PTx insensitive in NIH3T3 cells emphasizes the importance of host cell factors in modulating receptor function. Our previous study was performed in human VSMCs that express mainly {alpha}1B and {alpha}1D mRNA with very low {alpha}1A receptor subtype mRNA. A recent study in COS-7 cells demonstrated that {alpha}1B-receptor stimulation of MAP kinase involved a PTx-insensitive Gq{alpha} using a p21ras-independent mechanism, as it was found that overexpression of the P21N17ras dominant negative mutant did not inhibit {alpha}1B-receptor stimulation of MAP kinase (43).

Direct interactions between Gß{gamma}-subunits and protein kinases have been implicated in various cells. For example, Gß{gamma}-subunits stimulate PI 3-kinase in platelets and neutrophils (44, 45). Moreover, transfection studies with COS-7 cells revealed that Gß{gamma}-subunits activate MAP kinase after stimulation of Gs, Gi, and Gq-coupled receptors (46); these effects of the ß{gamma}-subunits are due to activation of p21ras (46). Gß{gamma}-subunits mediate tyrosine kinase receptor, IGF-I receptor activation of MAP kinase (47). van Biesen et al. (48) reported that {alpha}2-adrenergic receptors activate MAP kinase via stimulation of G protein ß{gamma}-subunits, leading to interactions of adapter proteins Grb2/SOS1/Shc, indicating that an intact signaling pathway machinery used by classical receptor tyrosine kinases is shared by G protein-coupled receptors. Based on these findings, Gß{gamma}-subunits, in G protein-coupled receptor signaling, have been suggested to be analogous to phosphorylated receptor tyrosine kinases (49).

In the present study, we obtained evidence that expression of {alpha}-transducin attenuated the norepinephrine-induced increase of PI-3 kinase activity in cells expressing {alpha}1B-receptors but not in cells expressing {alpha}1A-receptors, suggesting that ß{gamma}-subunits mediate {alpha}1B-receptor activation of PI-3 kinase. However, we found that overexpression of GRK2, ß-adrenergic receptor kinase peptide, used successfully to sequester ß{gamma}-subunits in other studies (47), did not inhibit {alpha}1B receptor-stimulated PI-3 kinase activity in our experiments (Fig. 3Go, A and B). This result raises the possibility that the ß{gamma}-subunits involved in {alpha}1B receptor-stimulated PI-3 kinase in NIH 3T3 cells have differing affinities for {alpha}tvs. GRK2. Since there are multiple forms of ß{gamma}-subunits, this possibility is tantalizing but requires further experimental testing.

A number of studies have suggested that there is a complex interaction between activation of PI 3-kinase and activation of the P21ras/MAP kinase cascade (17). For instance, several studies have demonstrated that activation of PI 3-kinase by growth factors or by G protein-coupled receptor agonists is associated with activation of p21ras. In PC12 cells, Downward et al. (50) demonstrated that PDGF-stimulated p21ras targets PI3-kinase. On the other hand, activation of PI 3-kinase may also function upstream of p21ras/MAP kinase cascade. A recent study suggests that the sequential activation of PI 3-kinase, Ras protein, and MAP kinase is involved in the insulin-signaling pathways during differentiation of adipocytes by hormones and phosphodiesterase inhibitors; inhibition of PI 3-kinase by wortmannin inactivated the Ras/MAP kinase pathway, leading to suppression of adipocyte differentiation (51). Other studies have demonstrated that PI 3-kinase activity is an important intermediate step in G protein-coupled receptor agonist activation of the p21ras-signaling cascade (22, 36). Hawes et al. (22) reported that stimulation of {alpha}2A-ARs or lysophosphatidic acid receptors activates p21ras and MAP kinase cascade via Gß{gamma}-subunits. Treatment of cells with specific inhibitors of PI 3-kinase, wortmannin or LY294002, or overexpression of a dominant negative mutant of the p85 subunit of PI 3-kinase, attenuated activation of the Ras/MAP kinase cascade. Moreover, a Gß{gamma}-specific PI 3-kinase {gamma} has recently been identified to mediate G protein-coupled receptor activation of MAP kinase cascades (52). Given the fact that {alpha}1B-receptor mediates MAP kinase activation via Gß{gamma}-subunits, it will be important to determine which subtype of PI 3-kinases (p85/p110 or p110 {gamma}) plays a signaling role in {alpha}1B-receptor signal transduction.

We recently found that {alpha}1-receptor stimulation of PI 3-kinase activity is associated with activation of Ras protein, and Ras may function as a target of PI 3-kinase in smooth muscle cells (36). Our present study provides evidence demonstrating that activation of PI 3-kinase is greatly involved in {alpha}1-receptor subtype-signaling pathways. Overexpression of the dominant negative mutant of p21A15Ras markedly inhibited the capacity of {alpha}1A- and {alpha}1B-receptor subtypes to activate p21ras (Fig. 4Go). This construct attenuated {alpha}1B-receptor-stimulated, but did not attenuate {alpha}1A receptor-stimulated, PI 3-kinase activity, suggesting that p21Ras may act either as downstream component of {alpha}1A receptor-stimulated PI 3-kinase or upstream component of {alpha}1B receptor-stimulated PI 3-kinase. However, overexpression of a dominant negative mutant of the PI 3-kinase p85 subunit, namely {Delta}p85, blocked {alpha}1A- but not {alpha}1B-receptor subtype-stimulated MAP kinase activity. This result demonstrates that PI 3-kinase is critical for activation of MAP kinase by {alpha}1A-receptors. However, the results suggest that {alpha}1B-receptor subtype activates PI 3-kinase and MAP kinase in parallel. There is other evidence indicating that {alpha}1- receptors may utilize other intracellular signal pathways such as protein kinase C/Raf-1 to activate MAP kinase independently of p21Ras (43). These complex interactions among the {alpha}1-receptors, subunits of G proteins, and downstream protein kinase cascades are presented schematically in Fig. 8Go.



View larger version (22K):
[in this window]
[in a new window]
 
Figure 8. Proposed Scheme of G Protein, PI 3-Kinase, and MAP Kinase Signaling Pathways Transduced by {alpha}1A- and {alpha}1B-Adrenergic Receptors

The data suggest that {alpha}1A- and {alpha}1B-receptors, coupled to PTx-insensitive G protein(s), have signaling mechanisms involving triggering by G{alpha}- or Gß{gamma}-subunits. The activated {alpha}- or ß{gamma}-subunits subsequently trigger PI 3-kinase, p21Ras, and MAP kinase or p21Ras and PI 3-kinase, respectively. The position of Ras, either upstream or downstream of PI 3-kinase, is different for these two {alpha}1-receptor subtypes.

 
In summary, the results indicate that {alpha}1A- and {alpha}1B-receptors activate PI 3-kinase, likely via different subunits of PTx-insensitive G proteins. Moreover, the {alpha}1A-receptor subtype may use Gq{alpha} and {alpha}1B receptor subtype may use ß{gamma}-subunits of Gq to stimulate PI 3-kinase activity in NIH3T3 cells. We also provide evidence demonstrating that increases in PI 3-kinase activity by stimulation of {alpha}1A-receptor subtype turn on p21ras activation, which in turn activates the MAP kinase cascade. However, {alpha}1B-receptor subtype activation of MAP kinase cascade is likely independent of activation of PI 3-kinase. These experiments demonstrate the heterogeneity of the signaling pathways activated by the various receptor subtypes. Further experiments aimed at understanding structure-function relationships for {alpha}1-receptor-coupling mechanisms should provide new insights into the functions of the physiologically very important receptor systems.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
Materials
Norepinephrine and myelin basic protein (MBP) were purchased from Sigma Chemical Co. (St Louis, MA); [{gamma}32P]ATP (2000 Ci/mmol), [{alpha}32P]dCTP, and enhanced chemiluminescence (ECL) Western detection system were purchased from Amersham Corp.(Arlington, IL); expression vectors of human {alpha}1A-, {alpha}1B-, and {alpha}1D-adrenergic receptor and control vectors were a gift of Dr. Johnston and colleagues of Central Research (Pfizer Inc., Sandwich, England); expression vectors of {alpha}-subunit of transducin ({alpha}t-pcDNA-I) and control vector (pcDNA-I) were kindly provided by Dr. Henry Bourne of University of California at San Francisco; expression vectors of a minigene (cDNA 495–689) of GRK2 (ß-ARK1) was a gift from Dr. R. J. Lefkowitz’s laboratory of Duke University (Durham, NC); the p21Ala15ras dominant negative mutant and control vectors were kindly provided by Joan H. Brown of University of California at San Diego; phosphatidylinositol was obtained from Avanti Polar Lipids Inc. (Alabaster, AL); human recombinant IGF-I, cell culture medium, and FBS were purchased from GIBCO/BRL (Grand Island, NY); wortmannin was from Worthington Biochemical Co. (Freehold, NJ); and antibodies against PI-3 kinase p85-{alpha}, p110, tyrosine protein kinases, H-ras, p44ERK1/2, GRK2, and {alpha}t, as well as protein A/G-agarose, were from Santa Cruz Biotechnology (Santa Cruz, CA). All other chemicals were reagent or molecular biology grade and were obtained from standard commercial sources.

Cell Culture
NIH3T3 mouse fibroblasts were purchased from the American Type Culture Collection (Manassas, VA). Cells were grown in DMEM with 5% FBS at 37 C in a humidified atmosphere of 5% CO2-95% air. The cells were harvested for passaging at confluence with trypsin-EDTA and plated in 100-mm dishes at a density about 5 x 105, with a 80–90% confluence being reached about 5 days later. The medium was replaced every 2 days. To examine effects of agonist-stimulated changes, cells were incubated with DMEM without serum for indicated times after achieving confluence. The cells were treated with agonists or vehicle solution (as control) starting from the longest time point, and the cells were harvested at the same time.

Stable Transfection of NIH3T3 Cells with {alpha}1-Adrenergic Receptors
NIH3T3 cells (3 x 105) were seeded in 100-mm2 culture dishes with DMEM with 10% FBS. The following day, each adrenergic receptor subtype expression vector ({alpha}1A and {alpha}1B, 10 µg; {alpha}1D, 50 µg) was transfected using 50 µg of lipofectamine (GIBCO-BRL) in serum-free medium after the instruction of manufacture. Five hours later, an equal volume of DMEM with 20% FBS was added. Twenty four hours after the start of transfection, the cells were washed and placed in fresh medium; 48 h later, the transfected cells were reseeded into ten 100-mm2 dishes, and culture medium was changed to DMEM/10% FBS with 500 µg/ml of Geneticin (GIBCO-BRL). Ten to 14 days later, the surviving cell colony was isolated and grown in medium containing Geneticin. Cells expressing a similar number of receptors were used for the further experiments. For various assays, the cells were made quiescent by serum starving for 24 h before treatment and harvest.

Transient Transfection of NIH3T3 Cells with Expression Vectors Containing {alpha}-Transducin, ß1-Adrenergic Receptor Kinase, p21Ala15ras, or p85{alpha}PI3K
Transfection of NIH3T3 cells with control or expression vectors containing {alpha}-transducin, ß1-adrenergic receptor kinase (now termed GRK2), the p21Ala15ras dominant negative mutant, or a dominant negative mutant of PI 3-kinase p85{alpha} ({Delta}P85) was performed as described above. NIH3T3 cells that stably expressed each of the three subtypes of {alpha}1-adrenergic receptors were cultured in DMEM with 10% FBS in the presence of 500 µg/ml of geneticin as described above. The cells were seeded into 100-mm2 dishes and transfected at ~80% confluence. Transfection was performed in 3.0 ml of Optim-MEM (GIBCO-BRL) containing 50 µg of lipofectamine and 10 µg of control vectors or expression vectors containing {alpha}-transducin, ß1-adrenergic receptor kinase, p21Ala15ras, or {Delta}P85. Five hours later, 3 ml of DMEM with 20% FBS were added. Twenty four hours from the start of transfection, the cells were washed, and fresh DMEM with 10% FBS was replaced. Next day, the cells were made quiescent by serum starving for 18 h before treatment and harvest. {alpha}1-Adrenergic receptor subtype-stimulated activation of PI 3-kinase, Ras-GTP, and MAP kinase was then determined as described below.

RNA Preparation and Northern Blotting Analysis
A single-step method of RNA isolation using acid guanidinium thiocyanate-phenol-chloroform extraction as described previously (53) was used to isolate total RNA from NIH3T3 cells. Briefly, cells were rinsed with cold calcium-magnesium-free PBS, and then the cells were homogenized with a Polytron in 10 vol of denaturing buffer containing 4 M guanidinium thiocyanate, 25 mM sodium citrate (pH 7), 0.5% sarcosyl, 0.1 M 2-mercaptoethanol. One volume of 2 M sodium acetate (pH 4.0), 10 vol of water-saturated phenol, and 2 vol of chloroform-isoamyl alcohol (49:1) were sequentially added to the homogenate with thorough mixing after addition of each reagent. The homogenate was incubated on ice for 20 min and then centrifuged at 12,000 x g for 20 min. The aqueous phase was taken and RNA was precipitated with isopropanol (1:1 volume). The resulting RNA pellet was dissolved in the denaturing buffer and again precipitated with isopropanol by cooling and centrifugation. The RNA pellet was washed with 75% ethanol, sedimented, vacuum dried, and dissolved in Tris-EDTA buffer. For Northern blotting analysis of c-fos, 10 µg of total RNA were heated at 65 C for 10 min, cooled rapidly on ice, and denatured with 6% formaldehyde. The RNA was fractionated by 1% agarose gel electrophoresis and transferred to a nylon filter by capillary blotting. The blot was prehybridized in 50% formamide, 5 x SSPE buffer (1 x SSPE = 0.18 M NaCl, 10 mM sodium phosphate, pH 7.7, and 1 mM EDTA), 5 x Denhardt’s solution, 0.5% SDS, at 42 C for 4 h, and hybridized at 42 C for 12–16 h to the rat c-fos or ß-actin cDNA probes that were labeled by [32P]dCTP using Amersham’s random priming labeling kit. After hybridization the filter was washed twice in 2 x SSPE, 0.1% SDS at 65 C for 15 min and once in 0.1 x SSPE, 0.1% SDS at 56 C for 30 min. The filter was exposed to Kodak XAR-5 film at -70 C with an intensifying screen for 16–24 h. The autoradiograms were scanned using a laser densitometer. The amount of c-fos mRNA was quantified relative to the amount of 18s tRNA on the same filter.

Immunoprecipitation
After treatment, cultures on 100-mm2 plates were rinsed with ice-cold PBS containing 1 mM sodium orthovanadate. Cells were incubated with lysis buffer (1% Nonidet P-40, 25 mM HEPES (pH 7.5), 50 mM NaCl, 50 mM NaF, 5 mM EDTA, 10 nM okadaic acid, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, and 10 µg/ml of antipain, aprotinin, and leupeptin) for 10–15 min on the ice. Insoluble material was removed by centrifugation at 12,100 x g for 20 min. The amount of cell lysate was normalized by protein content in each experiment using a kit from Bio-Rad (Richmond, CA). The lysate was incubated with an appropriate amount of antibody and agitated for 2 h. The lysate was further incubated with 20–30 µl of protein A/G plus-agarose with agitation for 1 h. The beads containing the immunoprecipitates were washed three times with lysis buffer, once with distilled water, and once with washing buffer (0.1 M NaCl, 1 mM EDTA, 20 mM Tris-HCl, pH 7.5), and subjected to PI 3-kinase and MAP kinase assays or analysis of Ras-bound GTP.

Analysis of Ras-Bound GTP and GDP
Agonist-stimulated change in Ras-bound GTP was performed following a method described previously (36). Quiescent cells were labeled with 0.1 mCi/ml of [32P]orthophosphate in phosphate-free DMEM for 12 h. After stimulation with agonists for the indicated times, cells were washed with cold PBS for three times and cells were lysed as described above. Ras proteins were recovered by immunoprecipitation with an anti-Ras polyclonal antibody. After extensively washing as described above, the immunoprecipitates were suspended in 20 µl of reaction mixture containing 20 mM HEPES, pH 7.5, 20 mM EDTA, 2% SDS, 0.5 mM GDP, and 0.5 mM GTP. The suspension was heated at 90 C for 3 min and centrifuged for 5 min. The bound nucleotides were separated by TLC on polyethyleneimine-cellulose plate with 0.75 M KH2PO4 for development. GDP and GTP were visualized using unlabeled standards. Ras-associated GTP was calculated from the ratio of GTP/(GDP+GTP). The radioactivity was quantitated with a PhosphorImager system (Molecular Dynamics, Sunnyvale, CA).

In Vitro Assays of PI 3-Kinase
For measurement of PI 3-kinase activity, cell lysates (1 mg protein) were incubated with antibody against the p85-{alpha} subunit of PI 3-kinase (2 µg/mg protein) as described above. Assay of PI 3-kinase activity was conducted as described previously (36). Briefly, the washed pellets were resuspended in 50 µl of kinase reaction buffer (20 mM Tris-HCl, pH 7.5, 100 mM NaCl, and 0.5 mM EGTA) and incubated at 25 C for 10 min after addition of 0.5 µl of 20 mg/ml phosphatidylinositol dissolved in chloroform to make micelles of PI. Assays were initiated with addition of 5 µl of ATP solution (0.4 M ATP, 0.1 M MgCl2, and 1 µCi/ml [{gamma}32P]ATP) and incubated at room temperature for 30 min. During this period of time the formation of phosphatidylinositol phosphate was linear (data not shown). The reaction was stopped upon addition of 100 µl of chloroform-methanol-11.6 N HCl (100:200:2). After centrifugation, the lower organic phase was taken for TLC on silica gel plates from J. T. Baker Inc. (Phillipsburg, NJ) and developed in chloroform-methanol-25% ammonium hydroxide-water (43:38:5:7). The plates were exposed to Kodak XAR-5 film at -70 C with an intensifying screen for 16–24 h or were visualized after development with a PhosphorImager system.

In Vitro Assay of MAP Kinase Activity
Assay of MAP kinase activity was performed following a method described previously (36). Confluent cells were incubated in the absence of serum overnight and treated with norepinephrine or other agonists for various times as indicated. The cells were lysed in 0.4 ml lysis buffer as described above. For MAP kinase activity assay, cell lysates (400 µg protein) were incubated with antibody against ERK1 (2 µg/mg protein) and washed as above. The washed immunocomplexes were resuspended in 50 µl of kinase buffer (25 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM dithiothreitol, 0.5 mM EGTA, 40 µM ATP, 1 µCi of [{gamma}32P]ATP), and MBP (1 mg/ml) as a substrate. The reaction mixture was incubated for 10 min at 30 C because preliminary experiments indicated that MBP-induced phosphorylation is linear for 20–30 min. The reaction was stopped by spotting 10 µl of reaction mixture onto p-81 phosphocellulose paper (Whatman LabSales, Hillsboro, OR), which was then washed in 75 mM phosphoric acid with constant stirring for 1 h and transferred to another washing overnight. The papers were washed with acetone for 5 min and dried. 32P, which represented the phosphorylation of MBP by MAP kinase, was quantitated by scintillation spectrophotometry. Alternatively, reaction mixtures were loaded and separated on 14% SDS-PAGE, and the dried gels were exposed to Kodak XAR-5 film at -70 C with an intensifying screen for 16–24 h for visualization.

Data Analysis
Data are presented as mean ± SEM, and treatment effects were compared by one-way ANOVA or Student’s paired t test (two tailed). P < 0.05 was taken as level of significance.


    ACKNOWLEDGMENTS
 
We thank Geoffrey Johnston for providing expression vectors encoding human {alpha}1A-, {alpha}1B-, and {alpha}1D-adrenergic receptors and control vectors; Joan H. Brown for providing the dominant negative mutant of p21Ras expression and control vectors; Henry R. Bourne for providing the {alpha}t and control constructs; and Wataru Ogawa for the dominant negative mutant of PI 3-kinase p85{alpha} and control vector.


    FOOTNOTES
 
Address requests for reprints to: Zhuo-Wei Hu, M.D., Ph.D., Veterans Affairs Palo Alto Health Care System, GRECC 182B, 3801 Miranda Avenue, Palo Alto, California 94304. E-mail: huzhwei{at}leland.stanford.edu

This work was supported by NIH Grant HL-41315 and by a preclinical grant from Pfizer Inc.

1 Supported by a Pharmaceutical Research and Manufacturers of America Foundation Fellowship for Careers in Clinical Pharmacology. Back

Received for publication December 4, 1997. Revision received August 17, 1998. Accepted for publication September 24, 1998.


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 

  1. Bylund DB, Regan JW, Faber JE, Hieble JP, Triggle CR, Ruffolo Jr RR 1995 Vascular alpha-adrenoceptors: from the gene to the human. Can J Physiol Pharmacol 73:533–543[Medline]
  2. Graham RM, Perez DM, Hwa J, Piascik MT 1996 Alpha 1-adrenergic receptor subtypes. Molecular structure, function, and signaling. Circ Res 78:737–749[Free Full Text]
  3. Miyazaki M 1994 Antihypertensive, antiatherosclerotic, and plasma lipid-lowering effects of monatepil, a novel calcium antagonist with alpha 1-adrenoceptor-blocking activity in experimental animals. Am J Hypertens 7(Pt 2):131S–140S
  4. Vargas HM, Gorman AJ 1995 Vascular alpha-1 adrenergic receptor subtypes in the regulation of arterial pressure. Life Sci 57:2291–2308[CrossRef][Medline]
  5. deBlois D, Schwartz SM, van Kleef EM, Su JE, Griffin KA, Bidani AK, Daemen MJ, Lombardi DM 1996 Chronic alpha 1-adrenoreceptor stimulation increases DNA synthesis in rat arterial wall. Modulation of responsiveness after vascular injury. Thromb Vasc Biol 16:1122–1129[Abstract/Free Full Text]
  6. Milano CA, Dolber PC, Rockman HA, Bond RA, Venable ME, Allen LF, Lefkowitz RJ 1994 Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci USA 91:10109–10113[Abstract/Free Full Text]
  7. Schomig A, Richardt G, Kurz T 1995 Sympatho-adrenergic activation of the ischemic myocardium and its arrhythmogenic impact. Herz 20:169–186[Medline]
  8. Michel MC, Kenny B, Schwinn DA 1995 Classification of alpha 1-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol 352:1–10[Medline]
  9. Hieble JP, Bylund DB, Clarke DE, Eikenburg DC, Langer SZ, Lefkowitz RJ, Minneman KP, Ruffolo RB 1995 International union of pharmacology. X. Recommendation for nomenclature of {alpha}-adrenoceptors: consensus update. Pharmacol Rev 47:267–270[Medline]
  10. Minneman KP 1988 Alpha 1-adrenergic receptor subtypes, inositol phosphates, and sources of cell Ca2+. Pharmacol Rev 40:87–119[Medline]
  11. Wu D, Jiang H, Simon MI 1995 Different {alpha}1-adrenergic receptor sequences required for activating different G alpha subunits of Gq class of G proteins. J Biol Chem 270:9828–9832[Abstract/Free Full Text]
  12. Muller S, Lohse MJ 1995 The role of G-protein beta gamma subunits in signal transduction. Biochem Soc Trans 23:141–147[Medline]
  13. Perez DM, DeYoung MB, Graham RM 1993 Coupling of expressed alpha 1B- and alpha 1D-adrenergic receptor to multiple signaling pathways is both G protein and cell type specific. Mol Pharmacol 44:784–795[Abstract]
  14. Nishio E, Nakata H, Arimura S, Watanabe Y 1996 Alpha-1-Adrenergic receptor stimulation causes arachidonic acid release through pertussis toxin-sensitive GTP-binding protein and JNK activation in rabbit aortic smooth muscle cells. Biochem Biophys Res Commun 219:277–282[CrossRef][Medline]
  15. Thorburn J, Thorburn A 1994 The tyrosine kinase inhibitor, genistein, prevents alpha-adrenergic-induced cardiac muscle cell hypertrophy by inhibiting activation of the Ras-MAP kinase signaling pathway. Biochem Biophys Res Commun 202:1586–1591[CrossRef][Medline]
  16. Deleted in proof
  17. Carpenter CL, Cantley LC 1996 Phosphoinositide kinases. Curr Opin Cell Biol 8:153–158[CrossRef][Medline]
  18. Carpenter CL, Cantley LC 1996 Phosphoinositide 3-kinase and the regulation of cell growth. Biochim Biophys Acta 1288:M11–16
  19. Nave B, Haigh TRJ, Hayward AC, Siddle K, Shepherd PR 1996 Compartment-specific regulation of phosphoinositide 3-kinase by platelet-derived growth factor and insulin in 3T3–L1 adipocytes. Biochem J 318:55–60[Medline]
  20. Yao R, Cooper GM 1996 Growth factor-dependent survival of rodent fibroblasts requires phosphatidylinositol 3-kinase but is independent of pp70S6K activity. Oncogene 13:343–351[Medline]
  21. Ettinger SL, Lauener RW, Duronio V 1996 Protein kinase C delta specifically associates with phosphatidylinositol 3-kinase following cytokine stimulation. J Biol Chem 271:14514–14518[Abstract/Free Full Text]
  22. Hawes BE, Luttrell LM, van Biesen T, Lefkowitz RJ 1996 Phosphatidylinositol 3-kinase is an early intermediate in the G beta gamma-mediated mitogen-activated protein kinase signaling pathway. J Biol Chem 271:12133–12136[Abstract/Free Full Text]
  23. Wilson M, Burt AR, Milligan G, Anderson NG 1996 Wortmannin-sensitive activation of p70s6k by endogenous and heterologously expressed Gi-coupled receptors. J Biol Chem 271:8537–8540[Abstract/Free Full Text]
  24. Chung J, Grammer TC, Lemon KP, Kazlauskas A, Blenis J 1994 PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase. Nature 370:71–75[CrossRef][Medline]
  25. Fry MJ 1994 Structure, regulation and function of phosphoinositide 3-kinases. Biochim Biophys Acta 1226:237–268[Medline]
  26. Bokoch GM, Vlahos CJ, Wang Y, Knaus UG, Traynor-Kaplan AE 1996 Rac GTPase interacts specifically with phosphatidylinositol 3-kinase. Biochem J 315:775–779[Medline]
  27. Stuart SM, Tetsuro H, Aaron HJM, Klippel A, Williams LT, Olefsky JM 1996 Activated phosphatidylinositol 3-kinase is sufficient to mediate actin rearrangement and GLUT4 translocation in 3T3–L1 adipocytes. J Biol Chem 271:17605–17608[Abstract/Free Full Text]
  28. Klippel A, Escobedo JA, Hu Q, Williams LT 1993 A region of the 85-kilodalton (kDa) subunit of phosphatidylinositol 3-kinase binds the 110-kDa catalytic subunit in vivo. Mol Cell Biol 13:5560–5566[Abstract]
  29. Stoyanov B, Volinia S, Hanck T, Rubio I, Loubtchenkov M, Malek D, Stoyanova S, Vanhaesebroeck B, Dhand R, Nurnberg B et al 1995 Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science 269:690–693[Medline]
  30. Klippel A, Escobedo JA, Fantl WJ, Williams LT 1992 The C-terminal SH2 domain of p85 accounts for the high affinity and specificity of the binding of phosphatidylinositol 3-kinase to phosphorylated platelet-derived growth factor beta receptor. Mol Cell Biol 12:1451–1459[Abstract]
  31. Zhang J, Benovic JL, Sugai M, Wetzker R, Gout I, Rittenhouse SE 1995 Sequestration of a G-protein ß{gamma} subunit or ADP-ribosylation of Rho can inhibit thrombin-induced activation of platelet phosphoinositide 3-kinases. J Biol Chem 270:6589–6594[Abstract/Free Full Text]
  32. Hu Q, Klippel A, Muslin AJ, Fantl WJ, Williams LT 1995 Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. Science 268:100–102[Medline]
  33. Burgering BM, Freed E, van der Voorn L, McCormick F, Bos JL 1994 Platelet-derived growth factor-induced p21ras-mediated signaling is independent of platelet-derived growth factor receptor interaction with GTPase-activating protein or phosphatidylinositol-3-kinase. Cell Growth Differ 5:341–347[Abstract]
  34. Sakaue H, Hara K, Noguchi T, Matozaki T, Kotani K, Ogawa W, Yonezawa K, Waterfield MD, Kasuga M 1995 Ras-independent and wortmannin-sensitive activation of glycogen synthase by insulin in Chinese hamster ovary cells. J Biol Chem 270:11304–11309[Abstract/Free Full Text]
  35. Yamauchi K, Holt K, Pessin JE 1993 Phosphatidylinositol 3-kinase functions upstream of Ras and Raf in mediating insulin stimulation of c-fos transcription. J Biol Chem 268:14597–14600[Abstract/Free Full Text]
  36. Hu ZW, Shi XY, Lin RZ, Hoffman BB 1996 Alpha1 adrenergic receptors activate phosphatidylinositol 3-kinase in human vascular smooth muscle cells. Role in mitogenesis. J Biol Chem 271:8977–8982[Abstract/Free Full Text]
  37. Okazaki M, Hu ZW, Fujinaga M, Hoffman BB 1994 Alpha 1 adrenergic receptor-induced c-fos gene expression in rat aorta and cultured vascular smooth muscle cells. J Clin Invest 94:210–218[Medline]
  38. Federman AD, Conklin BR, Schrader KA, Reed RR, Bourne HR 1992 Hormonal stimulation of adenylyl cyclase through Gi-protein ß{gamma} subunits. Nature 356:159–161[CrossRef][Medline]
  39. Ramirez MT, Post GR, Sulakhe PV, Brown JH 1995 M1 muscarinic receptors heterologously expressed in cardiac myocytes mediate Ras-dependent changes in gene expression. J Biol Chem 270:8446–8451[Abstract/Free Full Text]
  40. Crespo P, Xu N, Simonds WF, Gutkind JS 1994 Ras-dependent activation of MAP kinase pathway mediated by G-protein beta gamma subunits. Nature 369:418–420[CrossRef][Medline]
  41. Schwinn DA, Johnston GI, Page SO, Mosley MJ, Wilson KH, Worman NP, Campbell S, Fidock MD, Furness LM, Parry-Smith DJ, Peter B, Bailey DS 1995 Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues. J Pharmacol Exp Ther 272:134–142[Abstract]
  42. Llahi S, Fain JN 1992 Alpha 1-adrenergic receptor-mediated activation of phospholipase D in rat cerebral cortex. J Biol Chem 267:3679–3685[Abstract/Free Full Text]
  43. Hawes BE, van Biesen T, Koch WJ, Luttrell LM, Lefkowitz RJ 1995 Distinct pathways of Gi- and Gq-mediated mitogen-activated protein kinase activation. J Biol Chem 270:17148–17153[Abstract/Free Full Text]
  44. Stephens L, Smrcka A, Cooke FT, Jackson TR, Sternweis PC, Hawkins PT 1994 A novel phosphoinositide 3 kinase activity in myeloid-derived cells is activated by G protein beta gamma subunits. Cell 77:83–93[Medline]
  45. Thomason PA, James SR, Casey PJ, Downes CP 1994 A G-protein beta gamma-subunit-responsive phosphoinositide 3-kinase activity in human platelet cytosol. J Biol Chem 269:16525–16528[Abstract/Free Full Text]
  46. Faure M, Voyno-Yasenetskaya TA, Bourne HR 1994 cAMP and beta gamma subunits of heterotrimeric G proteins stimulate the mitogen-activated protein kinase pathway in COS-7 cells. J Biol Chem 269:7851–7854[Abstract/Free Full Text]
  47. Luttrell LM, van Biesen T, Hawes BE, Koch WJ, Touhara K, Lefkowitz RJ 1995 G beta gamma subunits mediate mitogen-activated protein kinase activation by the tyrosine kinase insulin-like growth factor 1 receptor. J Biol Chem 270:16495–16498[Abstract/Free Full Text]
  48. van Biesen T, Hawes BE, Luttrell DK, Krueger KM, Touhara K, Porfiri E, Sakaue M, Luttrell LM, Lefkowitz RJ 1995 Receptor-tyrosine-kinase- and G beta gamma-mediated MAP kinase activation by a common signalling pathway. Nature 376:781–784[CrossRef][Medline]
  49. Bourne HR 1995 Signal transduction. Team blue sees red. Nature 376:727–729[CrossRef][Medline]
  50. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J 1994 Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370:527–532[CrossRef][Medline]
  51. Uehara T, Tokumitsu Y, Nomura Y 1995 Wortmannin inhibits insulin-induced Ras and mitogen-activated protein kinase activation related to adipocyte differentiation in 3T3–L1 fibroblasts. Biochem Biophys Res Commun 210:574–580[CrossRef][Medline]
  52. Lopez-Ilasaca M, Crespo P, Pellici PG, Gutkind JS, Wetzker R 1997 Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase gamma. Science 275:394–397[Abstract/Free Full Text]
  53. Hu ZW, Shi XY, Hoffman BB 1996 Insulin and insulin-like growth factor I differentially induce alpha1-adrenergic receptor subtype expression in rat vascular smooth muscle cells. J Clin Invest 98:1826–1834[Abstract/Free Full Text]